Inductive Bio Secures $25M to Advance AI in Drug Discovery

Inductive Bio has raised $25 million in Series A funding to advance its AI-driven platform for small molecule drug discovery, announced in a press release. The funding round was led by Obvious Ventures, with participation from Andreessen Horowitz (a16z), Lux Capital, and other investors.

Inductive Bio's approach involves a pre-competitive data consortium where multiple companies contribute anonymized data, creating a foundational dataset for AI models to learn from real-world drug discovery programs. This data powers Inductive's Compass platform, which predicts a drug's ADMET properties before synthesis, aiding chemists in designing molecules with higher success potential.

The company plans to use the new funding to expand its AI model research and development, grow its data consortium, and deploy its technology across the industry. Inductive Bio aims to democratize AI tools in drug discovery, leveling the playing field for both startups and large pharmaceutical companies.